Maria Alexandrovna Aleshin, MD

Offices

4 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

10 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Aleshin’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

10 of 10 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A137604 · Current

Licensed to practise in California · since 2015 · expires 2027-03-31 · David Geffen School of Medicine at UCLA.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$44,526

Medicare paid this office $44,526 for 290 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	67	$8,423	$84
Short return visit (20+ min)	105	$7,762	$55
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	31	$5,946	$104
Short return visit (20+ min)	35	$2,695	$52
Destruction of precancer skin growth, 1 growth	47	$2,589	$46

See all 13 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	67	$8,423	$84
Short return visit (20+ min)	105	$7,762	$55
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	31	$5,946	$104
Short return visit (20+ min)	35	$2,695	$52
Destruction of precancer skin growth, 1 growth	47	$2,589	$46
Return visit (30+ min)	17	$2,459	$85
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	33	$2,394	$73
New patient visit (30+ min)	14	$1,025	$73
Punch biopsy, first skin growth	19	$863	$41
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes	20	$828	$41
Biopsy of related skin growth, first growth	28	$596	$19
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	26	$445	$15
Destruction of precancer skin growth, 2-14 growths	35	$306	$2

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Removal of skin lesions	177	More than 79% of doctors who do this
Removal or shaving of skin growth	1-10	None
Skin biopsy	89	More than 75% of doctors who do this

Who their Medicare patients are

290 Original Medicare patients in 2024. Average age 72 · Under 65 14% · 85 and older 12% · Women 60% · Also on Medicaid 28% · Health risk score 1.97. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 70% · Chronic kidney disease 30% · Coronary heart disease 27% · Diabetes 26% · Atrial fibrillation 24% · Depression 22% · Heart failure 21% · Cancer 17% · COPD 16% · Stroke 12% · Dementia 9%.

The office billed $234,074, Medicare allowed $60,956 and paid $44,526; for 975 services of 32 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	290	975	72	1.97	$234,074	$44,526
2023	292	969	71	1.90	$239,430	$47,706
2022	291	1,116	72	1.89	$257,264	$46,197
2021	295	966	71	2.06	$232,642	$43,839
2020	281	862	71	2.12	$211,196	$35,071
2019	258	989	71	1.78	$125,625	$30,721
2018	131	395	72	1.64	$56,158	$15,689

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 16 services

Sort by

Original Medicare services billed in 2023

Short return visit (20+ min)	108	$8,485	$55
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	20	$6,911	$110
Return visit (30+ min)	40	$4,835	$78
Short return visit (20+ min)	47	$3,875	$61
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	36	$3,512	$72
Destruction of precancer skin growth, 1 growth	53	$3,272	$47
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	22	$1,814	$76
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes	36	$1,671	$45
Return visit (30+ min)	12	$1,564	$82
New patient visit (30+ min)	16	$1,212	$76
Punch biopsy, first skin growth	22	$1,001	$42
New patient visit (30+ min)	15	$913	$61
Biopsy of related skin growth, first growth	19	$488	$24
Biopsy of related skin growth, first growth	12	$390	$30
Punch biopsy, each additional skin growth	15	$379	$24
Destruction of precancer skin growth, 2-14 growths	37	$281	$2

2022: 12 services

Sort by

Original Medicare services billed in 2022

Short return visit (20+ min)	129	$9,868	$55
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	71	$6,834	$64
Return visit (30+ min)	53	$5,813	$79
Destruction of precancer skin growth, 1 growth	68	$4,015	$46
New patient visit (30+ min)	48	$3,305	$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	16	$3,283	$94
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	27	$2,624	$90
Destruction of skin growth, 1-14 growths	17	$1,553	$62
Punch biopsy, first skin growth	29	$1,345	$43
Biopsy of related skin growth, first growth	52	$1,226	$21
Punch biopsy, each additional skin growth	19	$570	$24
Destruction of precancer skin growth, 2-14 growths	51	$526	$2

2021: 13 services

Sort by

Original Medicare services billed in 2021

Short return visit (20+ min)	108	$8,166	$55
Return visit (30+ min)	67	$7,916	$85
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	64	$5,975	$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	20	$4,011	$93
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	36	$3,409	$92
New patient visit (30+ min)	47	$3,089	$66
Destruction of precancer skin growth, 1 growth	57	$2,832	$42
Punch biopsy, first skin growth	25	$1,206	$45
Destruction of skin growth, 1-14 growths	12	$1,140	$60
Biopsy of related skin growth, first growth	33	$872	$22
New patient visit (15+ min)	20	$769	$38
Destruction of precancer skin growth, 2-14 growths	47	$414	$2
Punch biopsy, each additional skin growth	11	$340	$24

2020: 12 services

Sort by

Original Medicare services billed in 2020

Short return visit (20+ min)	126	$7,276	$41
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	64	$6,442	$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	14	$4,035	$96
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	32	$3,085	$93
Destruction of precancer skin growth, 1 growth	40	$2,198	$44
New patient visit (15+ min)	43	$1,571	$37
New patient visit (30+ min)	27	$1,551	$57
Return visit (30+ min)	13	$1,393	$66
Punch biopsy, first skin growth	27	$1,389	$46
Biopsy of related skin growth, first growth	27	$628	$21
Destruction of precancer skin growth, 2-14 growths	33	$349	$2
Punch biopsy, each additional skin growth	11	$298	$25

2019: 12 services

Sort by

Original Medicare services billed in 2019

Short return visit (20+ min)	109	$6,463	$41
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	38	$4,488	$65
New patient visit (30+ min)	63	$3,559	$56
Destruction of precancer skin growth, 1 growth	60	$3,469	$44
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	17	$1,859	$93
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	19	$1,701	$90
Biopsy of related skin growth, first growth	57	$1,503	$24
New patient visit (15+ min)	34	$1,349	$40
Destruction of precancer skin growth, 2-14 growths	47	$721	$2
Destruction of skin growth, 1-14 growths	11	$692	$63
Short return visit	19	$496	$22
Punch biopsy, first skin growth	11	$449	$41

2018: 10 services

Sort by

Original Medicare services billed in 2018

Short return visit (20+ min)	49	$2,280	$44
New patient visit (30+ min)	28	$1,885	$67
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	13	$1,833	$122
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	16	$1,830	$65
Biopsy of single growth of skin and/or tissue	39	$1,326	$34
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	11	$1,078	$90
Destruction of precancer skin growth, 1 growth	22	$1,027	$47
New patient visit (15+ min)	11	$494	$45
Short return visit	11	$270	$23
Destruction of precancer skin growth, 2-14 growths	20	$231	$2

Medicaid work

$9,180 in 2024

Medicaid paid $9,180 for 154 billed services this clinician did in 2024, up to 21 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Return visit (30+ min)	68	$4,743
Short return visit (20+ min)	86	$4,437

Sort by

Medicaid work by year

2024	154	2	21	$9,180
2023	172	2	21	$7,101
2022	69	2	16	$2,940
2021	29	2	15	$1,218
2020	76	1	19	$2,542
2019	108	1	21	$3,025
2018	14	1	14	$366

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Return visit (30+ min)	85	$4,344
Short return visit (20+ min)	87	$2,757

2022

Sort by

Largest Medicaid services in 2022

Return visit (30+ min)	57	$2,621
Short return visit (20+ min)	12	$320

2021

Sort by

Largest Medicaid services in 2021

Return visit (30+ min)	15	$804
Short return visit (20+ min)	14	$414

2020

Sort by

Largest Medicaid services in 2020

Short return visit (20+ min)	76	$2,542

2019

Sort by

Largest Medicaid services in 2019

Short return visit (20+ min)	108	$3,025

2018

Sort by

Largest Medicaid services in 2018

Short return visit (20+ min)	14	$366

Drugs they prescribed that Part D paid

$1,843,181

Pharmacies billed $1,843,181 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

611 generic and 167 brand-name prescriptions · $1,843,181 in drug cost · 45 antibiotic prescriptions to 23 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Humira(Cf)	24	$442,522	$18,438
Cosentyx Unoready	17	$283,254	$16,662
Dupixent	59	$209,343	$3,548
Dupixent	15	$63,808	$4,254
Clobetasol Propionate	57	$3,979	$70

See all 20 drugs

Sort by

Every Part D drug this clinician prescribed

Humira(Cf)	24	$442,522	$18,438
Cosentyx Unoready	17	$283,254	$16,662
Dupixent	59	$209,343	$3,548
Dupixent	15	$63,808	$4,254
Clobetasol Propionate	57	$3,979	$70
Clindamycin Phosphate	39	$1,677	$43
Tacrolimus	15	$1,136	$76
Ketoconazole	62	$909	$15
Metronidazole	15	$890	$59
Triamcinolone Acetonide	70	$683	$10
Fluocinonide	21	$673	$32
Metformin	18	$657	$36
Doxycycline Hyclate	24	$555	$23
Mupirocin	40	$316	$8
Hydrocortisone	62	$267	$4
Minoxidil	12	$201	$17
Spironolactone	11	$145	$13
Econazole Nitrate	11	$134	$12
Amoxicillin-Clavulanate Potass	12	$107	$9
Prednisone	11	$53	$5

Year by year

Sort by

Part D prescribing by year

2024	778	181	None	21%	$1,843,181
2023	711	165	None	14%	$1,054,054
2022	695	161	0% (0)	12%	$917,890
2021	544	134	0% (0)	10%	$631,971
2020	348	114	0% (0)	7%	$114,023
2019	309	121	0% (0)	9%	$110,167
2018	124	57	0% (0)	None	$12,101
2016	13	None	0% (0)	None	$2,300
2015	116	37	None	28%	$9,356
2014	122	28	0% (0)	27%	$5,027

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 21 drugs

Sort by

Part D drugs prescribed in 2023

Humira(Cf)	17	$251,380	$14,787
Tremfya	15	$188,852	$12,590
Dupixent	30	$106,104	$3,537
Ertapenem	23	$15,397	$669
Clobetasol Propionate	47	$3,218	$68
Tacrolimus	14	$1,814	$130
Fluocinonide	35	$1,794	$51
Fluorouracil	19	$1,767	$93
Ketoconazole	56	$1,319	$24
Valacyclovir	12	$1,033	$86
Doxycycline Hyclate	21	$994	$47
Clindamycin Phosphate	23	$790	$34
Ciclopirox	19	$645	$34
Triamcinolone Acetonide	51	$550	$11
Metronidazole	13	$547	$42
Hydroxyzine	12	$490	$41
Prednisone	38	$339	$9
Hydrocortisone	53	$295	$6
Minoxidil	11	$271	$25
Mupirocin	32	$227	$7
Econazole Nitrate	15	$178	$12

2022: 18 drugs

Sort by

Part D drugs prescribed in 2022

Humira(Cf)	18	$274,246	$15,236
Tremfya	13	$155,345	$11,950
Dupixent	18	$60,085	$3,338
Clobetasol Propionate	52	$4,742	$91
Fluorouracil	29	$2,845	$98
Fluocinonide	36	$2,091	$58
Ketoconazole	68	$1,311	$19
Clindamycin Phosphate	24	$1,204	$50
Triamcinolone Acetonide	76	$911	$12
Tretinoin	11	$577	$52
Ciclopirox	11	$511	$46
Prednisone	38	$463	$12
Hydrocortisone	69	$441	$6
Spironolactone	12	$396	$33
Ciclopirox	17	$390	$23
Doxycycline Hyclate	16	$315	$20
Mupirocin	32	$312	$10
Hydroxyzine	11	$112	$10

2021: 11 drugs

Sort by

Part D drugs prescribed in 2021

Humira(Cf)	14	$288,552	$20,611
Fluocinonide	39	$2,425	$62
Clobetasol Propionate	46	$2,087	$45
Fluorouracil	15	$1,299	$87
Ketoconazole	59	$1,113	$19
Triamcinolone Acetonide	74	$721	$10
Ciclopirox	19	$626	$33
Mupirocin	43	$439	$10
Hydrocortisone	54	$297	$5
Econazole Nitrate	12	$177	$15
Hydroxyzine	14	$85	$6

2020: 8 drugs

Sort by

Part D drugs prescribed in 2020

Clobetasol Propionate	32	$1,701	$53
Fluocinonide	30	$1,609	$54
Fluorouracil	14	$1,354	$97
Clindamycin Phosphate	19	$1,044	$55
Ketoconazole	44	$790	$18
Triamcinolone Acetonide	46	$465	$10
Hydrocortisone	31	$136	$4
Mupirocin	12	$121	$10

2019: 7 drugs

Sort by

Part D drugs prescribed in 2019

Fluocinonide	31	$1,333	$43
Ketoconazole	60	$1,128	$19
Fluorouracil	11	$1,072	$97
Clobetasol Propionate	23	$1,058	$46
Triamcinolone Acetonide	56	$814	$15
Hydrocortisone	25	$138	$6
Mupirocin	11	$124	$11

2018: 3 drugs

Sort by

Part D drugs prescribed in 2018

Fluocinonide	12	$668	$56
Triamcinolone Acetonide	25	$301	$12
Ketoconazole	15	$251	$17

2015: 3 drugs

Sort by

Part D drugs prescribed in 2015

Clopidogrel	11	$629	$57
Lisinopril	11	$124	$11
Metoprolol	12	$109	$9

2014: 4 drugs

Sort by

Part D drugs prescribed in 2014

Atorvastatin	23	$700	$30
Clopidogrel	12	$493	$41
Lisinopril	14	$160	$11
Metoprolol	13	$129	$10

Money from drug and device companies

$9,772 in 2025

Sort by

Industry payments by year

2025	2	9	$8,300	$9,772
2024	1	7	$6,725	$8,053
2023	2	10	$6,725	$8,091
2022	1	3	$500	$527
2019	1	1	None	$97

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Novartis Pharmaceuticals	Cosentyx	$9,700	7 payments Travel for Cosentyx · 2025-07-26 · $291 Meals for Cosentyx · 2025-07-26 · $122 Meals for Cosentyx · 2025-07-26 · $38 Consulting for Cosentyx · 2025-07-26 · $8,300 Travel for Cosentyx · 2025-07-26 · $236 Travel for Cosentyx · 2025-07-26 · $452 Travel for Cosentyx · 2025-07-25 · $261
E.R. Squibb & Sons L.L.C.	Sotyktu	$72	2 payments Meals for Sotyktu · 2025-08-24 · $59 Meals for Sotyktu · 2025-02-21 · $14

See all 9 published payments

Sort by

Every published payment

E.R. Squibb & Sons L.L.C.	Meals · 2025-08-24	Sotyktu	$59
Novartis Pharmaceuticals	Travel · 2025-07-26	Cosentyx	$291
Novartis Pharmaceuticals	Meals · 2025-07-26	Cosentyx	$122
Novartis Pharmaceuticals	Meals · 2025-07-26	Cosentyx	$38
Novartis Pharmaceuticals	Consulting · 2025-07-26	Cosentyx	$8,300
Novartis Pharmaceuticals	Travel · 2025-07-26	Cosentyx	$236
Novartis Pharmaceuticals	Travel · 2025-07-26	Cosentyx	$452
Novartis Pharmaceuticals	Travel · 2025-07-25	Cosentyx	$261
E.R. Squibb & Sons L.L.C.	Meals · 2025-02-21	Sotyktu	$14

See earlier years (2024, 2023, 2022, 2019)

2024: $8,053

Sort by

Payments by company in 2024

Novartis Pharmaceuticals	Cosentyx	$8,053	7 payments Meals for Cosentyx · 2024-11-02 · $22 Consulting for Cosentyx · 2024-06-08 · $6,725 Meals for Cosentyx · 2024-06-08 · $212 Travel for Cosentyx · 2024-06-08 · $322 Travel for Cosentyx · 2024-06-08 · $73 Travel for Cosentyx · 2024-06-07 · $643 Meals for Cosentyx · 2024-03-10 · $56

2023: $8,091

Sort by

Payments by company in 2023

Novartis Pharmaceuticals	Cosentyx	$7,975	9 payments Meals for Cosentyx · 2023-11-29 · $17 Meals for Cosentyx · 2023-09-21 · $36 Meals for Cosentyx · 2023-07-29 · $7 Travel for Cosentyx · 2023-04-16 · $519 Consulting · 2023-04-15 · $6,725 Meals · 2023-04-15 · $214 Travel · 2023-04-15 · $198 Travel for Cosentyx · 2023-04-14 · $247 Education for Cosentyx · 2023-02-16 · $12
Boehringer Ingelheim Pharmaceuticals	None	$116	1 payment Meals · 2023-07-29 · $116

2022: $527

Sort by

Payments by company in 2022

Abbvie	Humira	$527	3 payments Meals for Humira · 2022-07-23 · $5 Consulting for Humira · 2022-04-19 · $500 Meals for Humira · 2022-03-26 · $23

2019: $97

Sort by

Payments by company in 2019

Allergan	None	$97	1 payment Meals · 2019-03-02 · $97

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

ABBVIE INC. · M20-465 - A Study To Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate To Severe Hidradenitis Suppurativa · 2025	Their institution	$19,296
ABBVIE INC. · A Study To Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate To Severe Hidradenitis Suppurativa · 2025	Their institution	$9,674

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1861810558
Licence: CA A137604California A137604: Current · expires 2027-03-31
Trained: University of California, Geffen School of Medicine, 2014
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207N00000X (207N00000X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2014-03-31
NPI last updated: 2024-04-12
NPI record certified: 2024-04-12

This is when the NPI record was last certified, not a medical board exam.